RESUMEN
Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19. This work is to investigate the association between serum alpha-1-antitrypsin, hyperglycemia, and clinical outcomes in COVID-19, and community-acquired pneumonia, gastric cancer and renal cell carcinoma. Alpha-1-antitrypsin levels in serum was determined by the immunoturbidimetric method. We have set the level of alpha-1-antitrypsin in patients with community-acquired pneumonia and COVID-19 with or without hyperglycemia. Levels of alpha-1-antitrypsin in COVID-19 patients with hyperglycemia who survived > those who did not survive. Concentration of alpha-1-antitrypsin levels in COVID-19 men-patients with hyperglycemia who survived was significantly higher than compared with COVID-19 women-patients with hyperglycemia who survived. The obtained data convincingly demonstrate the value of testing the level of alpha-1-antitrypsin in the blood as one of the important indicators of the effectiveness of cancer diagnosis and prognosis.